DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 207 filers reported holding DENALI THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,502 | -30.5% | 218,194 | -0.6% | 0.05% | -27.0% |
| Q2 2023 | $6,476 | +26.9% | 219,448 | -0.9% | 0.06% | +23.5% |
| Q1 2023 | $5,103 | -11.1% | 221,500 | +7.3% | 0.05% | -15.0% |
| Q4 2022 | $5,742 | -99.9% | 206,500 | +16.5% | 0.06% | -6.2% |
| Q3 2022 | $5,438,000 | -1.4% | 177,196 | +3.3% | 0.06% | +18.5% |
| Q1 2022 | $5,517,000 | -27.9% | 171,496 | 0.0% | 0.05% | -20.6% |
| Q4 2021 | $7,648,000 | -11.6% | 171,496 | 0.0% | 0.07% | -16.0% |
| Q3 2021 | $8,652,000 | -36.9% | 171,496 | -1.9% | 0.08% | -35.7% |
| Q2 2021 | $13,711,000 | +73.6% | 174,796 | +26.4% | 0.13% | +61.5% |
| Q1 2021 | $7,897,000 | -28.1% | 138,296 | +5.4% | 0.08% | -29.1% |
| Q4 2020 | $10,989,000 | +133.8% | 131,196 | 0.0% | 0.11% | +107.5% |
| Q3 2020 | $4,701,000 | +48.2% | 131,196 | 0.0% | 0.05% | +39.5% |
| Q2 2020 | $3,172,000 | +38.1% | 131,196 | 0.0% | 0.04% | +18.8% |
| Q1 2020 | $2,297,000 | – | 131,196 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |